-
July 06, 2022
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM Agile Trial
-
January 20, 2022
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
-
November 16, 2021
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting
-
November 09, 2021
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
-
October 01, 2021
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
-
September 21, 2021
Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer
-
November 09, 2020
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
-
April 09, 2020
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
-
October 15, 2019
Vigeo Therapeutics to Present at the 2019 BIO Investor Forum
-
September 26, 2019
Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress
-
May 31, 2019
Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO
Toggle navigation